ClinicalTrials.gg
TerminatedNCT04925206ET-01Updated Mar 30, 2025

A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia

A Phase 1 interventional study of ET-01 in Transfusion Dependent Beta-Thalassaemia, sponsored by EdiGene (GuangZhou) Inc.. Terminated at 4 sites in China. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by EdiGene (GuangZhou) Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Development plan change

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Enrollment
20th of 34
8 · median 10
Started
2021
with 2 others
Phase 1
8 of 44
4 open now
Registered
16th of 44
by date
Lead sponsor
1 of 44
EdiGene (GuangZhou) Inc.

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 1, and was the 16th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open label, multi-center, single-dose phase 1 study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using ET-01.

03

Conditions studied

  • Transfusion Dependent Beta-Thalassaemia

Browse trials for

Keywords

  • Beta-Thalassaemia
  • CRISPR-Cas9
  • Human Hematopoietic Stem and Progenitor Cells
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects and/or legal representative fully understand and voluntarily sign forms.
  • Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol.
  • Be not appropriate to receive conventional hematopoietic stem cell transplantation.
  • Lansky/ score ≥ 70%.
  • Eligible for hematopoietic stem cell transplantation and conditioning with busulfan as per investigator's judgement.

Other protocol defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Subjects with associated α-thalassemia.
  • Subjects with any acute or uncontrolled infections.
  • History of uncontrolled epilepsy or other mental disorders.
  • Previous treatment with allogeneic bone marrow transplantation or gene therapy.

Other protocol defined exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    ET-01

    Biological: ET-01

Interventions

  • BiologicalET-01

    Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.

06

What researchers measure

Primary outcomes

  1. Frequency and severity of collected AEs & SAEs

    Time frame: Within 24 months after ET-01 infusion

  2. All-cause mortality

    Time frame: From signing of informed consent up to 24 months post-ET-01 infusion

  3. Incidence of transplant-related mortality

    Time frame: From baseline (pre-transfusion) up to 12 months post-ET-01 infusion

  4. Total lymphocyte count

    Time frame: Within 24 months after ET-01 infusion

  5. Proportion of subjects with abnormal proliferation of blood cells

    Time frame: Within 24 months after ET-01 infusion

07

Study locations

4 sites
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510623, China
  • Shenzhen Children's Hospital
    Shenzhen, Guangdong 518035, China
  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, Tianjin 300020, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jan 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 14, 2021
StartActual
Aug 17, 2021
Primary completionActual
Jan 30, 2024
CompletionActual
Mar 12, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04925206
Lead sponsor
EdiGene (GuangZhou) Inc.
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Aug 17, 2021
Primary completion
Jan 30, 2024
Completion
Mar 12, 2025
Last update
Mar 30, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ET-01

Start the discussion